#Denmark #Copenhagen #Glioblastoma #Curasight #uTREAT

Curasight's Landmark Phase 1 Trial for uTREAT: A New Hope for Glioblastoma Patients

Curasight A/S, a pioneering clinical-stage radiopharmaceutical company, has made substantial strides in the fight against high-grade gliomas, including the aggressive form glioblastoma. On January 12, 2026, the company released preliminary data from its Phase 1 clinical trial, which explores the potential of uTREAT—its first-in-class radiopharmaceutical designed to target the urokinase-type plasminogen activator receptor (uPAR) found predominantly in these malignancies.

Encouraging Findings from the Trial

The initial findings come from the first patient treated in the trial, with PET imaging revealing a clear and sustained uptake of uTREAT in the tumor. This groundbreaking result is vital, as it confirms that the drug effectively targets cancer tissues, with the signal from the PET scan lasting for at least 24 hours. The prolonged visibility indicates promising tumor binding capabilities, which could allow for more efficient radiation delivery.

Ulrich Krasilnikoff, CEO of Curasight, emphasized the significance of these findings, noting that the initial data marks an important milestone for both the company and the ongoing development of uTREAT. With high retention rates observed in the glioblastoma, this clinical validation enhances the prospects of uTREAT as a notable therapeutic option for multiple solid tumors expressing uPAR.

The Mechanism Behind uTREAT

Curasight's innovative approach leverages uPAR's role in tumor aggression, angiogenesis, and metastasis. The uTREAT mechanism is designed not only to identify but also to target high-grade gliomas and similar solid tumors up to 85% of which express uPAR. Currently, the trial continues recruiting more patients, with top-line data expected to be released by Q2 2026, further elucidating uTREAT's effectiveness.

Dosimetry and Safety Assessment

The Phase 1 trial is structured to evaluate the safety profile and dosing characteristics of uTREAT in patients diagnosed with glioblastoma. Participants are monitored closely for potential side effects and the overall efficacy of the radiopharmaceutical. The insights gleaned from this trial are crucial, as glioblastoma treatments have traditionally faced significant challenges due to the complexities of the tumor’s biology and its resistance to conventional therapies.

A Close Look at Glioblastoma

Glioblastoma represents a major area of unmet medical need, with over 30,000 new diagnoses yearly in the US and EU alone. This cancer type is notorious for its poor prognosis; nearly 50% of patients succumb within just 14 months post-diagnosis, and a mere 5% survive five years. Current therapies often involve external beam radiation, which, while effective, may come with severe side effects. The introduction of uTREAT could potentially alleviate some of these burdens by offering a targeted treatment option that minimizes damage to healthy brain tissue.

Conclusion

As Curasight embarks on the next stages of research, the promising initial data from the Phase 1 trial of uTREAT is paving the way for novel therapeutic strategies against aggressive gliomas. With expanded participation in the trial and further evaluations forthcoming, Curasight's advancements could represent a transformative leap in glioblastoma treatment and potentially reshape the oncology landscape. For continued updates on uTREAT and the trial progress, stakeholders and interested parties can follow Curasight’s developments closely through their official channels.